Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
Breaking Biology Technology:Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... Medicine Project of, Seattle (CHIMPS) Presented at Academic Pediatric Association Conference ... ... CHELMSFORD, Mass., April 22 El Salvador, like many,emerging markets, must ... public concern. This past fall, the El Salvadoran,government threatened to shut ...
... Comprise One of the Main User Groups of febit,s ... Simplified and Automated Microarray Technology, MEDFORD, Mass., and ... will introduce the Geniom RT Analyzer(R) to,the U.S. market at ... Boston., RNA-researchers, one of the main user groups of ...
... Netherlands and SANTA CLARA, Calif., April 22 /PRNewswire/,-- ... evolving field of molecular,diagnostics, and Agilent Technologies, Inc. ... they intend to collaborate to develop new in-vitro,diagnostic ... agreement in,which Agendia products will continue to be ...
Cached Biology Technology:ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 2ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 3ESA LeadCare(R) System Used to Identify Salvadoran Children with Lead Poisoning 4febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 2febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress 3Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 2Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement 3
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... perilous threats in today,s ocean. From overfishing and ... coral ecosystems are disappearing at unprecedented rates around ... corals surrounding the island of Moorea in French ... environment: coral guard-crabs. New research from the National ... Seabird McKeon and the museum,s predoctoral fellow Jenna ...
(Date:9/29/2014)... new study confirms that the exposure to tar tended ... of regular cigarettes. Similarly, exposure to nicotine tended ... popular type of cigarette in several countries around the ... certain toxic chemicals in the smoke of these cigarettes ... lower levels of chemicals in the smoke are not ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Slim cigarette smokers not exposed to more harmful chemicals 2
... function of a newly discovered gene in corn may ... reducing childhood blindness and mortality rates, according to a ... Chair of Translational Genomics and professor of agronomy at ... and particularly orange corn, a type he said likely ...
... of Michigan and Shanghai Jiao Tong University in ... renewable energy and biomedical research projects involving investigators ... renewable-energy program is to develop new technologies that ... climate change. The biomedical collaboration will spur technological ...
... This release is available in French . ... have genetically manipulated rats that can emulate Alzheimer,s disease in ... treatments. Alzheimer,s is a devastating brain condition leading to a ... research mice have been developed in the past, rats are ...
Cached Biology News:Orange corn holds promise for reducing blindness, child death 2U-M joins with Chinese university to jointly fund renewable energy and biomedical research projects 2
Polyclonal Antibody to SHPRH...
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Biotin anti-mouse Ly-49C/F/I/H...
Peptide-affinity Purified Polyclonal Antibody to Retinoic Acid-Induced 3 (RAI3/RAIG1)...
Biology Products: